TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04738643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Use Treatment Service and Varenicline Management
Description: The VM intervention builds upon the established TUT Service process. In addition to connecting the patient to TUT Service via electronic referral, it activates a medication management protocol that: 1) actively confirms no evidence of renal failure or pregnancy with oncology provider, 2) automates a referral to prescribing providers within the TUT Service team, prompting a call-back to patient within 24 hours, 3) provides written AVS instructions to contact TUT Service for initiation instructions and clinic appointment, and 4) pends a varenicline prescription to the medication list, ready for reconciliation by TUT Service prescribing clinicians. The protocol formalizes standard management principles for varenicline, including follow-up evaluation, pre-quit period duration, and side effect amelioration.
Study: NCT04905797

Intervention type: DIAGNOSTIC_TEST
Intervention: Stop Signal Task (CANTAB)
Description: The estimate of time where an individual can successfully inhibit their responses 50% of the time.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stop Signal Task (CANTAB)
Description: The estimate of time where an individual can successfully inhibit their responses 50% of the time.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stop Signal Task (CANTAB)
Description: The estimate of time where an individual can successfully inhibit their responses 50% of the time.
Study: NCT06047119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood pressure
Description: Blood pressure targets during general anesthesia and 2 hours after

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood pressure
Description: Blood pressure targets during general anesthesia and 2 hours after

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood pressure
Description: Blood pressure targets during general anesthesia and 2 hours after

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood pressure
Description: Blood pressure targets during general anesthesia and 2 hours after

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive end expiratory pressure
Description: Positive end expiratory pressure during general anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive end expiratory pressure
Description: Positive end expiratory pressure during general anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive end expiratory pressure
Description: Positive end expiratory pressure during general anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal volume
Description: Tidal volume during general anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal volume
Description: Tidal volume during general anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal volume
Description: Tidal volume during general anesthesia
Study: NCT06554535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab，Platinum-based Chemotherapy，Aspirin
Description: Participants will receive an induction therapy consisting of Serplulimab (4.5 mg/kg IV on Day 1), Carboplatin (AUC 5 IV on Day 1) or Cisplatin (75 mg/m² IV on Day 1), Etoposide (100 mg/m² IV on Days 1-3), and Bayer Aspirin (100 mg PO daily). This induction phase will be administered every 3 weeks for 4 cycles. Following the induction phase, participants will transition to a maintenance therapy phase where they will continue to receive Serplulimab (4.5 mg/kg IV on Day 1, every 3 weeks) and Bayer Aspirin (100 mg PO daily) until disease progression or intolerable toxicity.
Study: NCT06047119

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fraction of inspired oxygen
Description: Fraction of inspired oxygen during general anesthesia and 2 hours after

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fraction of inspired oxygen
Description: Fraction of inspired oxygen during general anesthesia and 2 hours after
Study: NCT04888117

Intervention type: PROCEDURE
Intervention: Laparoscopic cholecystectomy
Description: With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and laparoscopic instruments as well as a laparoscope are inserted to complete the cholecystectomy according to the surgeon's standard practice.

Intervention type: PROCEDURE
Intervention: Robotic-assisted cholecystectomy
Description: With the patient under general anesthesia, several small incisions are made in the abdomen. Ports are placed, the abdomen is insufflated, and the da Vinci Robotic Surgical System (Intuitive) is docked to the patient and used to complete the cholecystectomy according to the surgeon's standard of care.
Study: NCT05638633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 20 mg/ 5 mg
Description: Administration of prednisolone 20 mg for 5 days, followed by prednisolone 5 mg for 23 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone 20 mg/ 5 mg
Description: Administration of prednisolone 20 mg for 5 days, followed by prednisolone 5 mg for 23 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B compound (100mg B1, 50 mg B6, 500 µg B12)
Description: Administration of vitamin B compound for 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B compound (100mg B1, 50 mg B6, 500 µg B12)
Description: Administration of vitamin B compound for 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Vitamin B compound
Description: Administration of placebo for vitamin B compound placebo for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Vitamin B compound
Description: Administration of placebo for vitamin B compound placebo for 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Prednisolon
Description: Administration of placebo for prednisolone 20 mg for 5 days, followed by placebo for prednisolone 5 mg for 23 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Prednisolon
Description: Administration of placebo for prednisolone 20 mg for 5 days, followed by placebo for prednisolone 5 mg for 23 days.
Study: NCT05133531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Administered Intravenous (IV) per the protocol
Study: NCT04500392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula oxygenation
Description: Oxygen is supplied with a high-flow nasal cannula oxygenation device#the flow is up to 60L/min

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Regular nasal cannula
Description: Oxygen is supplied with a regular nasal cannula #the flow is up to 6L/min
Study: NCT05431387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytisinicline
Description: film-coated oral tablets containing 3 mg cytisinicline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: film-coated oral tablets containing matched placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral support
Description: Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral support
Description: Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.
Study: NCT04641728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 200 mg every three weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: olaparib 300 mg twice daily (BID)
Study: NCT05133531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Administered IV and subcutaneous (SC) per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Administered IV and subcutaneous (SC) per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Administered SC per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: Administered SC per the protocol
Study: NCT04798131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active neurofeedback procedure
Description: Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will continuously receive visual feedback computed from the fMRI signal analyzed with the hallucinations decoder. Patients will be trained to maintain the brain state associated with the no-hallucination state using appropriate coping strategies. A 5th fMRI scan will be performed at 1 month post-treatment.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham neurofeedback procedure
Description: Patients will perform 5 fMRI sessions. Four consecutive fMRI runs (1/ day) during which they will receive a random feedback and a 5th run at 1 month post-treatment.
Study: NCT06403280

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alcoholic drink
Description: Participants will receive vodka with rum flavored orange juice with a target blood alcohol of 0.4 ‰ 30 minutes after alcohol consumption. The required amount of vodka will be calculated with the Widmark formula.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Participants will receive a non-alcoholic rum flavored orange juice.
Study: NCT06195488

Intervention type: PROCEDURE
Intervention: Gastric ultrasound
Description: performing gastric ultrasound to determine gastric contents

Intervention type: PROCEDURE
Intervention: Gastric ultrasound
Description: performing gastric ultrasound to determine gastric contents
Study: NCT05444257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-121/TEZ/D-IVA
Description: Fixed-dose combination tablets for oral administration.
Study: NCT05133531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: Administered IV per the protocol
Study: NCT05972486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muse-S™ headband system
Description: Clinical grade, headband-style wireless EEG (electroencephalogram is a test used to evaluate the electrical activity in the brain) system and designed to interact with a mobile device (a smartphone or tablet). The device is a soft, stretchy band that fits around the forehead to the back of the head.
Study: NCT05228184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirosint®-SOL
Description: Dosage will be according to the USPI and Standard of Care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine Sodium
Description: Tablets will be crushed and dissolved in solution. Dosage will be according to the USPI and Standard of Care.
Study: NCT04826822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone + Dexamethasone
Description: Low doses of orally administered spironolactone and dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care SARS-CoV-2 treatment
Description: Standard-of-care SARS-CoV-2 treatment administered according to the local guidelines
Study: NCT05980559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeomin
Description: 50 units of Incobotulinumtoxin A (BTX A) Xeomin® Injections into the masseter and temporalis muscles bilaterally (15 Units per muscle applied with 2 injections in each masseter muscle) (10 Units per muscle applied with 2 injections in each temporalis muscle)
Study: NCT05519475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-HSD
Description: Administered by subcutaneous injection (SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by SC injection
Study: NCT06314672

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accrual
Description: Participate in AEP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accrual
Description: Participate in AEP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Discussion
Description: Participate in implementation discussions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: Participate in educational sessions/activities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: Participate in educational sessions/activities
Study: NCT05279300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS5001
Description: CS5001 will be administered every 3 weeks (21 days) by intravenous (IV) infusion, and 3 weeks (21 days) is considered as one treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS5001
Description: CS5001 will be administered every 3 weeks (21 days) by intravenous (IV) infusion, and 3 weeks (21 days) is considered as one treatment cycle.
Study: NCT05645952

Intervention type: OTHER
Intervention: Clinical follow up of hypertrophic cardiomyopathy
Description: Patients diagnosed with hypertrophic cardiomyopathy during study period
Study: NCT06352918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palmar grasp reflex stimulation
Description: This initiative is stimulated by applying gentle pressure to the palm of the baby's palm while he or she is awake, lying on a flat surface in a symmetrical supine position.
Study: NCT06228599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment Plan
Description: A matched treatment regimen will be administered for approximately 12 weeks based on recommendations made by the MTB.
Study: NCT06314672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Undergo interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Undergo interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Undergo interview

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Review
Description: Undergo data capture review

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT05159427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucotrol XL 5Mg Extended-Release Tablet
Description: Participants are randomized to take one tablet of this study drug by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glipizide ER 5 MG 24 HR Extended Release Oral Tablet
Description: Participants are randomized to take one tablet of this study drug by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin 200Mg Tab
Description: Participants will take one tablet of this study drug by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13C6-Glipizide
Description: Participants will take 1 mg of this study drug dissolved in 40 ml glucose solution by mouth.
Study: NCT05136664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer Powder for Oral Suspension (Part A)
Description: Participants initiate patiromer at an oral dose of 1 packet/day (8.4g/day as powder for suspension). The dose is adjusted ate the following visit based on local serum potassium (sK+) levels.~The content of each packet should be mixed with water, apple or cranberry juice before administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part B)
Description: Placebo is provided in packets, each containing 6 g of placebo as powder for suspension. Participants will take 1 packet per day, by mixing its content with water, apple or cranberry juice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patiromer Powder for Orals Suspension (Part B)
Description: Participants will continue to receive the same number of packets established during Part A, but dose may be up- or down titrated depending on sK+ levels.~The content of each packet should be mixed with water, apple or cranberry juice before administration.
Study: NCT06257472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: Participants will be mailed a Meta Quest 2 Headset. Participants will be asked to wear and use the VR headset for around 20 minutes each day for 8 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Virtual Reality Headset
Description: Participants will be mailed a Meta Quest 2 Headset. Participants will be asked to wear and use the VR headset for around 20 minutes each day for 8 weeks.
Study: NCT05630703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Attention Training in IBS
Description: The MB-IBS-EAT is an 8-week intervention with weekly 1-hour sessions in a web-based group format.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAP Diet
Description: Subjects in the FODMAP group will be provided dietary instructions by a registered dietician during weekly 1-hour sessions in a web-based group format
Study: NCT06154824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histamine
Description: Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cowhage
Description: 25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
Study: NCT05849012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Sulfur Diet
Description: Subjects will be placed on a low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Diet
Description: Subjects will continue on their usual diet for 8 weeks. At the end of 8 weeks, if participants are interested, they will be offered treatment with low sulfur diet for 8 weeks with the support of a nutritionist.~In addition, participants will be asked to complete: surveys, lactulose-mannitol test, glucose hydrogen breath test, blood samples, visceral sensation test, 24-hour urine sample for sulfate level, provide stool samples, optional colonoscopy.
Study: NCT06447129

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~The patients will do exercises under the control of the physiotherapist in the clinic.~The patient will perform the exercises with the verbal and visual commands of the physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: An 8-week exercise program used in conservative treatment of degenerative meniscus tears will be performed.~The patients will do exercises under the control of the physiotherapist in the clinic.~The patient will perform the exercises with the verbal and visual commands of the physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: The Neuromuscular Electrical Stimulation (NMES) will be applied for 20 minutes. The patient will be seated with hips and knees flexed at 90°. Electrodes will be placed on the proximal and distal ends of the vastus medialis obliquus and vastus lateralis muscles. The intensity will be increased as much as the patient can tolerate, and the patient will be asked to relax and not make voluntary muscle contractions.
Study: NCT04530552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT06226220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation
Description: Sacral neuromodulation (SNM) is a minimally invasive procedure that provides low-amplitude electrical stimulation to the S3 nerve root to improve micturition and defecation. Patients who elect to proceed with SNM undergo a trial phase to determine therapeutic response prior to placement of a permanent implantable pulse generator (IPG). A trial phase can be performed in two ways: a percutaneous nerve evaluation (PNE) or staged implantation. PNE involves the placement of a temporary wire connected to an electrode using external stimulation. It is performed in the office using local anesthesia. If the patient displays adequate improvement in symptoms (defined as \>50% improvement of symptoms from baseline), a permanent lead and subcutaneous IPG are implanted in the operating room.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral neuromodulation
Description: Sacral neuromodulation (SNM) is a minimally invasive procedure that provides low-amplitude electrical stimulation to the S3 nerve root to improve micturition and defecation. Patients who elect to proceed with SNM undergo a trial phase to determine therapeutic response prior to placement of a permanent implantable pulse generator (IPG). A trial phase can be performed in two ways: a percutaneous nerve evaluation (PNE) or staged implantation. PNE involves the placement of a temporary wire connected to an electrode using external stimulation. It is performed in the office using local anesthesia. If the patient displays adequate improvement in symptoms (defined as \>50% improvement of symptoms from baseline), a permanent lead and subcutaneous IPG are implanted in the operating room.
Study: NCT06313398

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biotin-labeled red blood cells
Description: Cellular Product (patient's own red blood cells washed in Biotin and infused back to patient)
Study: NCT06307743

Intervention type: PROCEDURE
Group type: OTHER
Intervention: rapid local ischemic postconditioning
Description: Rapid local ischemic postconditioning (RL-IPostC) is performed immediately (within 5 minutes) after revascularization. A balloon guiding catheter (BGC) positioned on ipsilateral C1 segment of internal carotid artery is inflated and deflated for the temporary occlusion of the antegrade flow.
Study: NCT06226545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LASN01
Description: Low dose of LASN01 will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LASN01
Description: High dose of LASN01 will be administered intravenously.